FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.8.4  |  FHIR Version n/a  User: [n/a]

1495581000168106: List of Medicines for Brand Consideration reference set (foundation metadata concept)


Status: current, Primitive. Date: 30-Sep 2020. Module: Third party reference set module

Descriptions:

Id Description Lang Type Status Case? Module
4462321000168116 List of Medicines for Brand Consideration reference set (foundation metadata concept) en Fully specified name Active Initial character case insensitive Third party reference set module
4462331000168118 List of Medicines for Brand Consideration reference set en Synonym Active Initial character case insensitive Third party reference set module
4462411000168119 List of Medicines for Brand Consideration (LMBC) reference set en Synonym Active Initial character case insensitive Third party reference set module
4462641000168118 <p>Supports the identification of AMT Medicinal Product Unit of Use (MPUU) and Medicinal Product Pack (MPP) concepts associated with the List of Medicines for Brand Consideration (LMBC) that forms part of the Active Ingredient Prescribing initiative. Under the <i>National Health (Pharmaceutical Benefits) Regulations 2017</i>, the <i>Repatriation Pharmaceutical Benefits Scheme Instrument 2013</i> and <i>MRCA Pharmaceutical Benefits Scheme Instrument 2013</i>, all PBS and RPBS prescriptions must be prepared by active ingredient, the brand may additionally be identified if a prescriber considers it necessary. The LMBC supports prescribers' decision-making regarding the inclusion of brand on a prescription.</p><p>This reference set can be used by prescribing software vendors to identify medications for brand consideration to meet Active Ingredient Prescribing requirements.</p><p><b>Target Client:&nbsp;</b>This reference set was developed by the National Clinical Terminology Service for the Australian Government Department of Health and Aged Care to support the Active Ingredient Prescribing initiative, and can be used by developers to assist with the requirements.</p> en Definition Active Case sensitive Third party reference set module


1324 members. Search Members:

Expanded Value Set


Outbound Relationships Type Target Active Characteristic Refinability Group Values
List of Medicines for Brand Consideration reference set Is a Reference sets for Medications true Inferred relationship Some
List of Medicines for Brand Consideration reference set Is a Simple type reference set true Inferred relationship Some
List of Medicines for Brand Consideration reference set Developed by Australian Government Department of Health and Aged Care true Inferred relationship Some 1570063879

Members
fluorometholone acetate 0.1% eye drops, 5 mL
flupentixol decanoate 100 mg/mL injection, ampoule
flupentixol decanoate 100 mg/mL injection, 5 x 1 mL ampoules
flupentixol decanoate 20 mg/mL injection, ampoule
flupentixol decanoate 20 mg/mL injection, 5 x 1 mL ampoules
fluticasone furoate 100 microgram/actuation powder for inhalation, 14 actuations
fluticasone furoate 100 microgram/actuation powder for inhalation, 30 actuations
fluticasone furoate 100 microgram/actuation powder for inhalation, actuation
fluticasone furoate 200 microgram/actuation powder for inhalation, 14 actuations
fluticasone furoate 200 microgram/actuation powder for inhalation, 30 actuations
fluticasone furoate 200 microgram/actuation powder for inhalation, actuation
fluticasone propionate 100 microgram/actuation powder for inhalation, 60 actuations
fluticasone propionate 100 microgram/actuation powder for inhalation, actuation
fluticasone propionate 250 microgram/actuation powder for inhalation, 60 actuations
fluticasone propionate 250 microgram/actuation powder for inhalation, actuation
fluticasone propionate 500 microgram/actuation powder for inhalation, 60 actuations
fluticasone propionate 500 microgram/actuation powder for inhalation, actuation
follitropin alfa 300 units (21.84 microgram)/0.5 mL injection, pen device
follitropin alfa 300 units (21.84 microgram)/0.5 mL injection, 0.5 mL pen device
follitropin alfa 300 units (22 microgram)/0.5 mL injection, cartridge
follitropin alfa 22 microgram / 0.5 mL injection, 0.5 mL pen device (medicinal product unit of use)
follitropin alfa 300 units (22 microgram)/0.5 mL injection, 0.5 mL cartridge
follitropin alfa 300 units (22 microgram)/0.5 mL injection, 0.5 mL pen device
follitropin alfa 300 units (22 microgram)/0.5 mL injection, 10 x 0.5 mL pen devices
follitropin alfa 300 units (22 microgram)/0.5 mL injection, 5 x 0.5 mL pen devices
follitropin alfa 450 units (32.76 microgram)/0.75 mL injection, pen device
follitropin alfa 450 units (32.76 microgram)/0.75 mL injection, 0.75 mL pen device
follitropin alfa 450 units (33 microgram)/0.75 mL injection, cartridge
follitropin alfa 450 units (33 microgram)/0.75 mL injection, pen device
follitropin alfa 450 units (33 microgram)/0.75 mL injection, 0.75 mL cartridge
follitropin alfa 450 units (33 microgram)/0.75 mL injection, 0.75 mL pen device
follitropin alfa 450 units (33 microgram)/0.75 mL injection, 10 x 0.75 mL pen devices
follitropin alfa 450 units (33 microgram)/0.75 mL injection, 5 x 0.75 mL pen devices
follitropin alfa 900 units (65.52 microgram)/1.5 mL injection, 1.5 mL pen device
follitropin alfa 900 units (65.52 microgram)/1.5 mL injection, pen device
follitropin alfa 900 units (66 microgram)/1.5 mL injection, 1.5 mL cartridge
follitropin alfa 900 units (66 microgram)/1.5 mL injection, cartridge
formoterol fumarate dihydrate 12 microgram/actuation powder for inhalation, 60 actuations
formoterol fumarate dihydrate 12 microgram/actuation powder for inhalation, actuation
formoterol fumarate dihydrate 12 microgram powder for inhalation, 1 capsule
formoterol fumarate dihydrate 12 microgram powder for inhalation, 10 capsules
formoterol fumarate dihydrate 12 microgram powder for inhalation, 30 capsules
formoterol fumarate dihydrate 12 microgram powder for inhalation, 60 capsules
hydromorphone hydrochloride 10 mg/mL injection, ampoule
hydromorphone hydrochloride 10 mg/mL injection, 10 x 1 mL ampoules
hydromorphone hydrochloride 10 mg/mL injection, 5 x 1 mL ampoules
hydromorphone hydrochloride 4 mg modified release tablet
hydromorphone hydrochloride 4 mg modified release tablet, 10
hydromorphone hydrochloride 4 mg modified release tablet, 100
hydromorphone hydrochloride 4 mg modified release tablet, 14
hydromorphone hydrochloride 4 mg modified release tablet, 20 tablets (medicinal product pack)
hydromorphone hydrochloride 4 mg modified release tablet, 28
hydromorphone hydrochloride 4 mg modified release tablet, 30
hydromorphone hydrochloride 4 mg modified release tablet, 35
hydromorphone hydrochloride 4 mg modified release tablet, 40
hydromorphone hydrochloride 4 mg modified release tablet, 50
hydromorphone hydrochloride 4 mg modified release tablet, 60
hydromorphone hydrochloride 4 mg modified release tablet, 7
hydromorphone hydrochloride 4 mg tablet
hydromorphone hydrochloride 4 mg tablet, 10
hydromorphone hydrochloride 4 mg tablet, 100
hydromorphone hydrochloride 4 mg tablet, 20
hydromorphone hydrochloride 4 mg tablet, 500 tablets (medicinal product pack)
hydromorphone hydrochloride 4 mg tablet, 60
hydromorphone hydrochloride 50 mg/5 mL injection, 10 x 5 mL ampoules
hydromorphone hydrochloride 50 mg/5 mL injection, ampoule
hydromorphone hydrochloride 50 mg/5 mL injection, 5 x 5 mL ampoules
hydromorphone hydrochloride 500 mg/50 mL injection, 50 mL vial
hydromorphone hydrochloride 500 mg/50 mL injection, vial
hydromorphone hydrochloride 8 mg modified release tablet
hydromorphone hydrochloride 8 mg modified release tablet, 10
hydromorphone hydrochloride 8 mg modified release tablet, 100
hydromorphone hydrochloride 8 mg modified release tablet, 14
hydromorphone hydrochloride 8 mg modified release tablet, 20
hydromorphone hydrochloride 8 mg modified release tablet, 28
hydromorphone hydrochloride 8 mg modified release tablet, 30
hydromorphone hydrochloride 8 mg modified release tablet, 35
hydromorphone hydrochloride 8 mg modified release tablet, 40
hydromorphone hydrochloride 8 mg modified release tablet, 50
hydromorphone hydrochloride 8 mg modified release tablet, 60
hydromorphone hydrochloride 8 mg modified release tablet, 7
hydromorphone hydrochloride 8 mg tablet
hydromorphone hydrochloride 8 mg tablet, 10
hydromorphone hydrochloride 8 mg tablet, 100
hydromorphone hydrochloride 8 mg tablet, 20
hydromorphone hydrochloride 8 mg tablet, 60
incobotulinumtoxinA 100 units injection, 1 vial
incobotulinumtoxinA 100 units injection, vial
incobotulinumtoxinA 50 units injection, 1 vial
incobotulinumtoxinA 50 units injection, vial
leuprorelin acetate 22.5 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack
leuprorelin acetate 30 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack
leuprorelin acetate 45 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack
leuprorelin acetate 7.5 mg modified release injection [1 syringe] (&) inert substance diluent [1 syringe], 1 pack
somatropin 4 mg injection [1 vial] (&) inert substance diluent [1 vial], 1 pack
somatropin 1 mg injection [1 chamber] (&) inert substance diluent [0.25 mL chamber], 1 dual chamber syringe
somatropin 1 mg injection [1 chamber] (&) inert substance diluent [0.25 mL chamber], 7 dual chamber syringes
somatropin 1.2 mg injection [1 chamber] (&) inert substance diluent [0.25 mL chamber], 1 dual chamber syringe
somatropin 1.2 mg injection [1 chamber] (&) inert substance diluent [0.25 mL chamber], 7 dual chamber syringes
somatropin 1.4 mg injection [1 chamber] (&) inert substance diluent [0.25 mL chamber], 1 dual chamber syringe
somatropin 1.4 mg injection [1 chamber] (&) inert substance diluent [0.25 mL chamber], 7 dual chamber syringes

Start Previous Page 7 of 14 Next End


Reference Sets

Australian dialect reference set

Reference set descriptor

Back to Start